Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imaging

Shakil S, Chen D, Isquith D, Sapp J, Pommier I, Chu B, Guo Y, Canton G, Balu N, Yuan C, Hatsukami T, Maynard C, Zhao[...]

Differences in Ambulatory Care Outcomes Between Trainees and Faculty: A Multi-center Study

Graham KL, Amat M, Norian E, Li J, Weintraub J, Shaik A, Boggan JC, Davy J, Lyons A, Semour L, Rogers R, Davis RB. Differences[...]

Comparative assessment of CAC and SIS plaque burden categories via AI-guided quantitative CT analysis

Iskander B, Ichikawa K, Punnanithinont N, Kambalapalli S, Kinninger A, Krishnan S, Lakshmanan S, Roy S, Budoff MJ. Comparative assessment of CAC and SIS plaque[...]